Jump to content
  • Sign Up

Admin

Root Admin
  • Content Count

    2,474
  • Joined

  • Last visited

Everything posted by Admin

  1. IP.Content 2.0 uses the term "frontpage" to refer to both the homepage of the Articles module, and the landing page of each individual category. We have introduced this new navigational structure to better allow you to showcase content, while presenting it in a standardized format that your users will be able to understand and jump into without assistance. Firstly, you will now be able to define "frontpage" templates in the ACP for the Articles module. IP.Content will ship with 3 defaults: 1x2x2 Layout This layout will display articles in a traditional "news" style layout. Blog format This format will display articles in a blog-style format. Single column This layout will force articles to display in a single column, one per row. You can use one or more of these frontpage layouts, or you can create your own. Experiment with displaying articles in different formats on your homepage to determine which layout your users like best. Articles must be set to "Show on front page" in order for them to display on the homepage frontpage. In addition to the homepage frontpage, each category has it's own frontpage. The category frontpage functions identically to the homepage frontpage, except for two important factors: Only records from within that category (and it's subcategories) will be displayed The "Show on front page" setting is not honored for the category frontpage You will be able to easily review and manage the articles set to display on the frontpage from a new section of the ACP labeled "Frontpage Manager". We feel that this new area of the articles section will help showcase important articles and increase user interaction with your articles section.
  2. In the IP.Content ACP, you will notice that there are 3 separate template sections of the ACP: Block Templates Page Templates Database Templates Article Templates Within each templates section, you can create containers to group your templates into logical groupings. For instance, you may wish to create a grouping for each database you create, and then place the database templates appropriately into the container representing the database itself. Or you may wish to create multiple front page templates, and group them all together in the article templates area. You can use containers for whatever purposes you may have, or not at all: it's up to you! Templates can be reordered by dragging and dropping the rows up and down, and they can be moved from one container to another via drag n drop as well. Certain meta data about the templates are stored when you create new database or article templates, allowing IP.Content to tailor other areas of the ACP to help you out. For example, the software stores the template type when you create a new template. This allows us to show only "category listing" templates in the "category listing template" selection dropdowns. Similarly, the template tag help panel can automatically know which template type you are editing without you having to specify. Properly making use of templates can help you push out pages on your site in a uniform manner quickly and easily, and without having to "reinvent the wheel" each time a new page is ready to be published.
  3. The page management module interface has many powerful tools built in, designed to help you work with pages and folders in IP.Content efficiently. Firstly, the folder navigation utilizes AJAX to load the folder contents inline without requiring you to visit a new page to view the contents of the folder. We have also updated some common management features to utilize AJAX to help facilitate management of your pages. Actions like clearing folders and deleting folders, for instance, will now occur without page refreshes, making your managerial activities flow smoother and quicker. Additionally, the interface as a whole has been updated to provide a nicer, smoother feel for the page management areas. In practice, we found that many administrators spend the majority of their time setting up and utilizing IP.Content in the page management areas, so we wanted to update the user interface to make this experience as easy and enjoyable as possible. Minor details like confirmation dialogs have been updated to bring everything together for a more consistent feel. A new filter bar, utilizing AJAX to retrieve the results without the need for a page refresh, has also been added to the page management area. You can begin typing in the name of a page and a live-search action will occur in the background, showing you the results of your search as you type. If you have many pages and many folders (and many pages within those many folders), you will find that using the filter bar to locate your pages can dramatically speed up your navigation of IP.Content within the page management areas of the ACP. Overall, we've modernized the IP.Content page management area of the ACP, polishing up the little details, in an effort to make your experience all the more pleasant.
  4. IP.Content allows you to promote posts from your forums to articles in the IP.Content Articles database. The administrator can configure the specifics of this feature in the ACP under My Apps -> IP.Content -> Promote Article Settings. You can turn the system on and off, control which groups can copy and move posts to the articles section, and specify a few other details for the feature. A new hook is included with IP.Content which adds a button to each post labeled "Promote to Article". This button only shows up if you have permission to use the feature based on the ACP configuration. When clicked, the button will take you to a new form where you can formalize the details of the new article. You can tweak the text and title, upload an image, and specify other pertinent details. If you are able to both move and copy posts to the articles section, you will also be asked which type of promotion you wish to use. Upon submitting the form, IP.Content handles the rest. This new feature can be used to showcase important content otherwise hidden in your forums by pushing this content to your frontpage. It is then up to you whether you want a copy made in the articles section (leaving the original post in tact), whether you want to actually move the post to the articles section, and whether you want any cross-linking left in place. With such powerful options, we are sure you will find many uses for this great tool available in IP.Content.
  5. I am pleased to announce the inaugural edition of the Journal of the Rosacea Research & Development Institute is now available from iUniverse. The proceeds of the sale of this journal will be used to further the journal's publication and lead to some novel rosacea research. This journal took over two years to develop and the RRDi had many volunteers to publish this. Joanne Whitehead, Ph.D., is the editor in chief of the Journal of the RRDi and she worked countless hours making this a reality. Thanks for your support by purchasing a copy.
  6. Some of the MAC Members reply to questions by email to me and I then publish the answers for them. Here is a reply from Kosta Y. Mumcuoglu, PhD regarding this topic question: BEGIN REPLY: It is known that patients with papulopustular rosacea have a higher density of Demodex folliculorum mites on their faces than normal subjects but their role in initiating inflammation is disputed. It was reported that when the number of Demodex mites increases, there is a higher chance to develop a bacterial infection and inflammation, which could be considered as a result of the mite activity and damage caused. Selective antibiotics are effective in reducing the inflammatory changes of papulopustular rosacea, but their mode of action is unknown. Lately, a bacterium (Bacillus oleronius) was isolated from a D. folliculorum mite extracted from the face of a patient with papulopustular rosacea. To investigate whether this mite-related bacterium was capable of expressing antigens that could stimulate an inflammatory immune response in patients with rosacea, Lacey et al. (2007) investigated patients with rosacea and control subjects and found that in the presence of bacterial antigens, the proliferation of peripheral blood mononuclear cells was significantly higher in patients with rosacea than in control subject. Accordingly, it is thought that mite-related bacteria have the potential to stimulate an inflammatory response in patients with papulopustular rosacea. Li et al. (2010) investigated the correlation between ocular Demodex mite infestation and sero-positivity of the patients to B. oleronius in 49 patients with facial rosacea. Facial rosacea, lid margin, and ocular surface inflammation were documented by photography. There was a significant correlation between serum immunoreactivity (presence of the bacterium) and facial rosacea, lid margin inflammation, and ocular Demodex infestation. The Demodex count was significantly higher in patients with positive facial rosacea. The strong correlation provides a better understanding of co-morbidity between Demodex mites and their symbiotic B. oleronius in facial rosacea and blepharitis. Treatments directed to both warrant future investigation. References: Li J, O'Reilly N, Sheha H, Katz R, Raju VK, Kavanagh K, Tseng SC. Correlation between Ocular Demodex Infestation and Serum Immunoreactivity to Bacillus Proteins in Patients with Facial Rosacea. Ophthalmology. 2010 Jan 14. [Epub ahead of print] Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007 Sep;157(3):474-81. Kosta Y. Mumcuoglu, PhD END REPLY
  7. This is to announce that two new MAC members have volunteered to serve on the RRDi MAC: Craig A. Elmets, M.D., Chairman, Department of Dermatology University of Alabama School of Medicine and Alan B. Fleischer Jr, M.D., Professor and Chair of the Department of Dermatology at Wake Forest University The RRDi appreciates these two physicians volunteering to help us.
  8. Here are replies by email: From: Robert Brodell, MD Subject: Re: Questions for the RRDi MAC Members Date: February 12, 2010 2:49:14 AM HST To: Barrows Brady Misdiagnosed Rosacea Why do you think there are reports of misdiagnosed rosacea? The diagnosis is rosacea is easy of a patient has acne papules and pustules in association with a red face. However, some patients have a form of rosacea with mostly redness and telangiectasias. Without the acne component visible, the differential diagnosis includes chronic sun-damaged skin, flushing and blushing, acute lupus, drug induced erythema, and other conditions. In some cases, patients have a combination of several causes for their facial redness. While in most patients the diagnosis of acne rosacea is easy, some patients with facial redness due to other causes may be called rosacea, and some patients with rosacea may be missed even when physicians are smart and mean well. Robert Brodell, MD _____________________________________________________________ Reply from Brady Barrows to Dr. Brodell: Here is the evidence for misdiagnosed rosacea: Click Here _____________________________________________________________
  9. Replies sent by email: From: Robert Brodell,MD Subject: Re: Questions for the RRDi MAC Members Date: February 12, 2010 2:49:14 AM HST To: Barrows Brady Oracea Long Term Use How long should Oracea be prescribed? Oracea is a low-dose doxycycline formulated to have a slow release component so that the level of drug in a patient's system is lopw at any given time. This insures that the doxycycline is working as an anti-inflammatory drug rather than an antibiotic which minimizes side effects including stomach upset, yeast infections, and the potential for developing bacteria that are resistant to this drug. This makes it an excellent drug for rosacea. While physicians never want patients to be on any oral drug longer than they need it, some patients with rosacea require long term treatment. I have patients who have been on Oracea for years since every time I try to stop the medication their condition flares up, despite attempts to suppress their rosacea with a variety of topical medications. So, How long should Oracea be prescribed? Ans> As long as needed to keep rosacea under control....and,.... as short as possible! Robert Brodell, MD ____________________________________________________________
  10. Galderma after it acquired Collegenex's brand Oracea, which is described as "Capsules 40 mg are hard gelatin capsule shells filled with two types of doxycycline beads (30 mg immediate release and 10 mg delayed release) that together provide a dose of 40 mg of anhydrous doxycycline," is marketing this as a first line of treatment for rosacea and as the 'only FDA approved oral medication for rosacea." The Prescribing Information Sheet from Galderma says that "Efficacy beyond 16 weeks and safety beyond 9 months have not been established." There are numerous reports that Oracea has been prescribed well over 9 months. What do you think about prescribing Oracea beyond the safety threshold described in the sheet mentioned above? Should rosaceans expect to be prescribed Oracea long term in amount such as years?
  11. The subject of misdiagnosed rosacea usually comes up when there is a discussion or articles about rosacea. I am curious what the MAC members think about misdiagnosed rosacea and why it occurs? What would be the most obvious reason a misdiagnosis occurs? Is it because the definition of rosacea is sometimes vague? The initial history and physical exam is cursory? Or is there another reason why this occurs? If there are several reasons what might they include? Here is list of articles and anecdotal reports of misdiagnosing rosacea.
  12. Tanweer A. Syed (Timothy Syed Andersson) is no longer affiliated in any way with the RRDi.
  13. This is to announce that Noah Scheinfeld, M.D. has joined our Medical Advisory Committee [MAC] as a consultant to the RRDi and you may view his photo and CV at this page. Dr. Scheinfeld has a background not only in dermatology serving on the faculty at Columbia University but also a background in law having graduated from Harvard law school. The RRDi greatly appreciates his volunteering to help us.
  14. The following replies to this thread were sent to me by email: From: Robert Brodell, M.D. Subject: Re: Calcium, Vitamin D(3), And Retinoic Acid Date: January 23, 2010 2:16:31 AM HST To: Barrows Brady Basic science research is important because it often points up approaches to disease treatment that would not be otherwise apparent. HOWEVER, acne rosacea is a complicated process and I would not recommend any changes to the treatment of patients without clinical evidence of efficacy. Bob -------------------------------------------------------
  15. A new PubMed article abstract by Dr. Gallo concludes: "These findings show that the expression and activity of KLK are under fine control and can be distinctly influenced by variables such as differentiation, calcium, vitamin D, and RA. Thus, these variables may further control the functions of antimicrobial peptides in the skin." Does this mean that rosaceans should increase their intake of calcium, vitamin D and RA? What comments do you have about this research?
  16. A new study which Dr. Tseng participated in entitled, Correlation between Ocular Demodex Infestation and Serum Immunoreactivity to Bacillus Proteins in Patients with Facial Rosacea, was just announced today on PubMed. Could Dr. Tseng or any of the other MAC members interpret what the results of this study might mean for us? It is rather scientific and needs some translation into layman's tongue with your thoughts on this study, please.
  17. Thanks Dr. Jones. From what I have been learning from the MAC members is that what the public thinks about rosacea research grants is quite different from what the medical or scientific community thinks. Do you have any comments on the current published or non published rosacea research being sponsored by the NRS or the AARS?
  18. Some of the RRDi MAC Members have replied to my question by email and here is the list: From: Latkany, MD Robert Subject: RE: Question for RRDi MAC Members Date: December 24, 2009 12:52:11 AM HST To: Barrows Brady Not all grant recipients publish their results but the majority should. A submission of a paper should be required but not all papers are guaranteed acceptance. But if you are given money a paper should be submitted. The results should not influence additional funding as this introduces conflict of interest. Robert Latkany, MD ___________________________________________________________________________________________ From: Robert Brodell Subject: Re: Question for RRDi MAC Members Date: December 24, 2009 2:38:30 AM HST To: Barrows Brady Picking a winner is as difficult in funding research as it is in horse racing. Several approaches can be taken. The most common approach is to have a committee of experts review grant applications and choose grantees that 1) have a proven track record in previous research in the area; 2) Have a solid plan that is feasible; 3) will provide important basic science information that can, hopefully, be translated into clinical treatments. However, this is by no means the only approach to funding research. The American Cancer Society saw a problem with research funding 50 years ago. Young researchers could not get their first grant to get started because it would be impossible for them to have a track record. Therefore, they began funding young researchers for their first grant...only requiring that they perform research applicable to the cancer problem. This approach has led to the initial funding of 43 investigators who have won the Nobel Prize in Science! My conclusion, develop a thoughtful system utilizing stakeholders with rosacea and noted clinicians and scientists. Stick to your guns and don’t put pressure on anyone to do anything BUT, make an effort to publish their research. Recognize that research that does not pan out is harder to get into the literature than research that identifies positive findings. Therefore, it is not the fault of the investigator if their reseach does not get published...they must, however, make a good faith effort. Robert Brodell, MD __________________________________________________________________________________________ From: raymond peat Subject: Re: Question for RRDi MAC Members Date: December 31, 2009 7:14:51 PM HST To: Barrows Brady It's good to be able to consult experts when judging the applications, but I think it's important to have some judges who aren't dermatologists. The existence of a large group of interested people communicating through the website could itself make a considerable contribution to productive research. Raymond Peat, Ph.D. ______________________________________________________________________________ From: Peter Drummond Subject: RE: update on the Journal of the RRDi Date: January 2, 2010 4:36:47 PM HST To: Barrows Brady I have thought a little bit about the questions you posted on the forum about supporting rosacea research. I agree that one of the primary criteria for supporting research grant applications should be the track record of the applicants (whether publications have arisin from previous support, number of PhD students supervised, presentations at conferences etc). Of course the ultimate aim is to advance treatments for rosacea, but as progress has to depend on insights into pathophysiology it would be important to support fundamental as well as applied research. Regards, Peter Drummond, Ph.D. _______________________________________________________________________________________________________________________________________________________________________________
  19. This is an open question to the RRDi MAC members about grant writing since we hope someday that the RRDi will be sponsoring our own grants and would like to know more about the process of grant writing and how it works. We hope the MAC members will give us some insight into what kinds of grants we should sponsor and thoughts on the following questions: There are now two non profit organizations taking the lead in sponsoring rosacea research grants: National Rosacea Society American Acne & Rosacea Society The NRS has the lead in sponsoring rosacea research by spending over the past 12 years a reported $962,696 on 45 reported grants. The AARS has spent $30,000 on three grants. My questions are the following: Of the total of 45 grants sponsored by the NRS only nine have been published. The three grants by the AARS haven't been published yet. Shouldn't the sponsors of grants look for awarding grants to those who get published, or does this matter? Secondly, of the nine grants that were published (or for that matter all the grants sponsored), shouldn't the results of new treatments be one of the criteria for judging whether or not to continue sponsoring further research on a subject? I haven't heard of any new treatments as the result of any of the grants sponsored by the NRS or the AARS. Are there any new treatments resulting from any of the sponsored research so far? Here is a breakdown of the published results of completed NRS sponsored research: (1) The role of vascular endothelial growth factor in rosacea Dr. Mina Yaar, professor of Dermatology, Boston University School of Medicine. Publication of results: Kosmadaki MG, Yaar M, Arble BL, Gilchrest BA. UV induces VEGF through a TNF-alpha independent pathway. Federation of American Societies for Experimental Biology Journal 2003;17:446-448. (2) Influence of skin temperature on bacteria in rosacea Dr. Mark V. Dahl, chairman of Dermatology, Mayo Clinic Scottsdale, and Dr. Patrick M. Schlievert, professor of Microbiology, University of Minnesota Medical School. Publication of results: Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. Journal of the American Academy of Dermatology 2004;50:266-272. (3) Immune system may trigger onset of rosacea symptoms Dr. Richard Gallo, associate professor of dermatology and pediatrics at the University of California - San Diego and Dr. Masamoto Murakami, postdoctoral scientist, Veterans Medical Research Center. Publication of results: Yamasaki K, Barden A, Taylor K, Wong C, Ohtake T, Murakami M, Gallo RL. Expression and potential pathological role of cathelicidin expression in rosacea [abstract]. The Journal of Investigative Dermatology 2004;122:A51. Abstract 301. (4) The role of bacterial antigen(s) in the etiology and persistence of papulopustular bacteria. Dr. Kevin Kavanagh, Department of Biology, National University of Ireland - Maynooth, and Dr. Frank Powell, consultant dermatologist, Mater Misericordiae Hospital, Dublin. Publication of results: Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. British Journal of Dermatology 2007;157:474-481. (5) Perceptions of self in persons with rosacea. Karol Burkhart Lindow, RN, C, CNS, assistant professor of nursing; Deb Shelestak, RN, MSN; Joan Lappin, RN, MSN, Kent State University. Publication of results: Lindow KB, Shelestak D, Lappin J. Perceptions of self in persons with rosacea. Dermatology Nursing 2005;17(4):249-254,3 (6) Glycomics analyses of tear fluid for the diagnostic detection of ocular rosacea. Dr. Mark J. Mannis, Department of Ophthalmology, University of California - Davis. Publication of results: An HJ, Ninonuevo M, Aguilan J, Liu H, Lebrilla CB, Alvarenga LS, Mannis MJ. Glycomics analyses of tear fluid for the diagnostic detection of ocular rosacea. Journal of Proteomic Research 2005 Nov-Dec;4(6):1981-7. (7) Allergy-like reaction may trigger inflammation in rosacea Dr. Richard L. Gallo, associate professor of dermatology and pediatrics at the University of California - San Diego, and Dr. Kenshi Yamasaki, Veterans Medical Research Center Publication of results: Yamasaki K, DiNardo A, Bardan A, et al. Increased serine protease activity and cathelicidins promotes skin inflammation in rosacea. Nature Medicine 2007;13:975-980. (8) Cell biologic effects of ATP on endothelial cells Dr. Richard Granstein, chairman, Department of Dermatology, Cornell University. Publication of results: Seiffert K, Ding W, Wagner JA, Granstein RD. ATPγS enhances the production of inflammatory mediators by a human dermal endothelial cell line via purinergic receptor signaling. Journal of Investigative Dermatology 2006;126:1017-1027 (9) Mite-related bacteria may induce rosacea inflammation Dr. Kevin Kavanagh, Department of biology, National University of Ireland, Maynooth, and Dr. Frank Powell, Consultant Dermatologist, Mater Misericordiae Hospital, Dublin. Publication of results: Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. British Journal of Dermatology 2007;157:474-481. Source of the above published results ________________________________ Do you have any comments on any of the sponsored published rosacea research that would enlighten us on what the RRDi should be looking at to sponsor?
  20. It is with sorrow that we just learned that Karl Rebert passed away October 9, 2009 at the age of 29. Karl joined the RRDi April 5, 2008. He had a background in pharmaceutical chemistry and was quite knowledgeable about rosacea treatment. He volunteered to help edit the new journal and I asked him if he would volunteer also to serve on the board of directors which he gladly did. He worked many hours of volunteer service to the RRDi editing and proof reading the journal. Karl will be missed.
  21. Dr. Tseng, Could you answer a couple of questions about the following report: Study finds cause of rosacea Can you explain if you feel that the cause of rosacea has really been found as the article above suggests? What can you tell us about this study and is there an abstract available on this study with PubMed? Thanks.
  22. Thanks for the tip mchatham. I haven't heard of this product before. Maybe we will hear more good reports like yours with this product? I can't find how to buy this stuff on the the net. What is the link?
  23. The RRDi is please to announce that Joanne Whitehead, Ph.D., has been appointed to serve on the board of directors: http://irosacea.org/....php#jwhitehead Dr. Whitehead has written an article for the RRDi which will be published later this year by the RRDi and has been pre-published by Elsiever: http://www.ncbi.nlm....5?dopt=Abstract The RRDi is a non profit organization of volunteer rosacea sufferers who have come together to find the cure for rosacea.
  24. Admin

    Rosacean Dating

    Maybe this is the place? Have you found any other site for dating rosaceans?
  25. Valerie Fox has announced her resignation from the board of directors. Valerie graciously volunteered to serve on the RRDi board of directors from the start of this organization but is too busy to serve on the board anymore. I personally what to thank Valerie for all her volunteer efforts and how she was instrumental in getting our non profit status approved by the State of Hawaii and the IRS. We will miss Valerie and wish her the best in her career.
×
×
  • Create New...